B
Bristol-Myers Squibb
Bristol-Myers Squibb settled a $10 million antitrust class action involving Evotaz and Atripla HIV drugs.
ClosedUnited States-wideClaim status: Closed on June 27, 2022Payout: VariesNo longer claimable
About this settlement
The settlement addresses alleged antitrust violations affecting the cost of Evotaz and Atripla HIV medications.
This settlement resolves antitrust claims against Bristol-Myers Squibb related to the pricing of Evotaz and Atripla HIV drugs. Eligible claimants include patients and purchasers who paid for these drugs during the specified period.
Who qualifies
- Patients, purchasers, or entities who paid for brand-name or generic Evotaz or Atripla.
- Payments made between May 14, 2015 and October 13, 2021.
Varies
Claim status: Closed on June 27, 2022